Literature DB >> 19553070

Clinical experience of Ganz surgical dislocation approach for metal-on-metal hip resurfacing.

Paul E Beaulé1, Paul Shim, Kamlajeet Banga.   

Abstract

Although the posterior approach is the most commonly used for hip resurfacing, concerns remain in terms of risk of femoral neck fracture secondary to an osteonecrotic event. The purpose of this study was to look at the short-term results of metal-on-metal hip resurfacing done by the vascular-preserving surgical approach as developed by Ganz in 116 hip resurfacing arthroplasties performed in 106 patients (86 men, 20 women; mean age, 46.5 years; range, 19-62). At a mean follow-up of 38.3 months (range, 12-84), Harris Hip Scores improved significantly from 53.1 to 90.16 (P < .001). There were 10 nonunions (8.7%) and 21 hips (18.3%) requiring screw removal for painful bursitis. Two hips underwent conversion to total hip arthroplasty: one at 18 months for femoral loosening and one at 7 years for acetabular loosening. Although the trochanteric slide approach as developed by Ganz provides excellent exposure to the hip joint and preserves femoral head vascularity, it does carry some inherent morbidity in regard to the greater trochanter.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553070     DOI: 10.1016/j.arth.2009.04.006

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  3 in total

Review 1.  Hip resurfacing: a systematic review of literature.

Authors:  Régis Pailhé; Akash Sharma; Nicolas Reina; Etienne Cavaignac; Philippe Chiron; Jean-Michel Laffosse
Journal:  Int Orthop       Date:  2012-10-26       Impact factor: 3.075

2.  Birmingham hip resurfacing: five to eight year results.

Authors:  Aleksi Reito; Timo Puolakka; Jorma Pajamäki
Journal:  Int Orthop       Date:  2010-06-19       Impact factor: 3.075

Review 3.  Metal-on-metal hip resurfacing arthroplasty: an analysis of safety and revision rates.

Authors:  S Sehatzadeh; K Kaulback; L Levin
Journal:  Ont Health Technol Assess Ser       Date:  2012-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.